BACKGROUND AND AIMS: The prevalence of @entity1561 ( @entity1561 ) and @entity1560 ( @entity43458 ) is increasing at an alarming rate. The role of @entity3645 in the development and progression of @entity1561 to @entity43458 and @entity82 is poorly understood. This study aimed to quantify the @entity6741 metabolome in healthy subjects and @entity1 with non-cirrhotic @entity43458 under fasting conditions and after a standardized meal. METHODS: Liquid chromatography tandem mass spectroscopy was used to quantify 30 serum and 16 urinary @entity3645 from 15 healthy volunteers and 7 @entity1 with biopsy-confirmed @entity43458 . @entity6741 concentrations were measured at two fasting and four post-prandial time points following a high-fat meal to induce @entity1085 and @entity6741 reabsorption from the intestine. RESULTS: @entity1 with @entity43458 had significantly higher total serum @entity6741 concentrations than healthy subjects under fasting conditions (2.2- to 2.4-fold increase in @entity43458 ; @entity43458 2595-3549    M and healthy 1171-1458    M) and at all post-prandial time points (1.7- to 2.2-fold increase in @entity43458 ; @entity43458 4444-5898    M and healthy 2634-2829    M). These changes were driven by increased @entity2226 - and @entity8959 -conjugated primary and secondary @entity3645 . @entity1 with @entity43458 exhibited greater variability in their fasting and post-prandial @entity6741 profile. CONCLUSIONS: Results indicate that @entity1 with @entity43458 have higher fasting and post-prandial exposure to @entity3645 , including the more hydrophobic and cytotoxic secondary species. Increased @entity6741 exposure may be involved in @entity99 and the pathogenesis of @entity1561 and @entity43458 .

Altered XXXX Metabolome in @entity1 with @entity1561 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity2226 :: ('MESH:D013654', 'Chemical') :: ['taurine'] @entity1085 :: ('MESH:D005705', 'Disease') :: ['gallbladder contraction'] @entity82 :: ('MESH:D005355', 'Disease') :: ['cirrhosis'] @entity8959 :: ('D005998', 'Chemical') :: ['glycine'] @entity1560 :: ('MESH:D005234', 'Disease') :: ['steatohepatitis'] @entity1561 :: ('MESH:D065626', 'Disease') :: ['NAFLD', 'nonalcoholic fatty liver disease'] @entity6741 :: ('CHEBI:3098', 'Chemical') :: ['bile acid', 'Bile acid'] @entity3645 :: ('MESH:D001647', 'Chemical') :: ['bile acids'] @entity99 :: ('MESH:D056486', 'Disease') :: ['liver injury'] @entity43458 :: ('64092', 'Gene') :: ['NASH']
@entity6741 :: (CHEBI:3098,Chemical) :: ['Bile Acid']
